top of page

We're dedicated to defeating cancer drug resistance.

Over 90% of cancer patient mortality is due to drug resistance and most clinical trials fail due to drug resistance

Blocking resistance to drug treatment will transform the lives of millions

Our proprietary synthetic lethality screening platform, Resistome™, rapidly identifies drug-specific resistance mechanisms and evaluates drug combinations which overcome drug-specific resistance to extend life for patients, as well as identifying refined biomarker strategies to improve the stratification of patients for treatment.

We partner with Pharmaceutical and Biotechnology companies to provide foresight of drug resistance that will appear in the clinic and develop improved patient stratification strategies for greater success in the clinical trials.

Using Resistome™ technology we discover novel pathways, drugs and combinations to overcome cancer drug resistance

Resistance drastically reduces a drug's clinical benefit triggering relapse and patient death

  • only 15 % of patients receiving therapy will gain clinical benefit.

  • 2 out of 3 patient's tumors harbor innate resistance to drug treatment and will remain without a therapeutic solution.

Resistance to drugs in clinical trials is a significant causes  of failure

  • 90% of cancer clinical trials fail.

  • 57% due to lack of efficacy/resistance.

  • 17% due to toxicity.

Resistome™ enables:

  • The identification of drug-specific genes/proteins and signaling resistance pathways.

  • The rapid, parallel evaluation of multiple drug combinations to overcome resistance.

  • Preclinical: for a given drug:

    • (i) which indication harbors minimal resistance.

    • (ii) which combination will block resistance and convert the resistant cohort to a responding cohort.

    • (iii) prioritize the drugs progressed to clinical phase based on the lack or presence of resistance.

  • Clinical: Indication extension: Which combination is required to enable treatment for a given new indication.

  • Rescue of drugs which failed due to lack of efficacy.

  • Perform a screen to identify novel drug targets.

  • Improved biomarker strategies for better inclusion/exclusion criteria.

  • The rapid determination of on- and off-target effects to understand a drugs' mechanism of action and toxicity.

bottom of page